Stock Market Preview: Summit Therapeutics, Cleveland-Cliffs, Dynex Capital, HBT Financial Earnings Expected October 20

Summit Therapeutics (SMMT) and Cleveland-Cliffs (CLF) are expected to report a 75% and 45% decrease in earnings per share, respectively, for Q3 2025. Dynex Capital (DX) is expected to see a 540% increase in earnings per share, while HBT Financial (HBT) is expected to see a 1.64% increase. The 2025 Price to Earnings ratio for SMMT is -19.13, while CLF's is -6.03, DX's is 7.17, and HBT's is 9.38.

Investors are eagerly awaiting the Q3 2025 earnings reports from Summit Therapeutics (SMMT), Cleveland-Cliffs (CLF), Dynex Capital (DX), and HBT Financial (HBT). The earnings outlook for these companies paints a diverse picture, with significant changes expected in earnings per share (EPS) and Price to Earnings (P/E) ratios.

Summit Therapeutics (SMMT)
Summit Therapeutics is expected to report a 75% decrease in EPS for Q3 2025, with analysts estimating an EPS of $-0.08, according to Benzinga. Historically, the company has shown volatility in its earnings performance, with significant price movements following earnings releases. The current P/E ratio for SMMT is -19.13, indicating a challenging financial environment.

Cleveland-Cliffs (CLF)
Cleveland-Cliffs is expected to see a 45% decrease in EPS for Q3 2025, with analysts estimating an EPS of $-0.46, according to Benzinga. The company has a history of earnings volatility, with recent quarters showing both significant increases and decreases in share price. The current P/E ratio for CLF is -6.03, reflecting the company's financial challenges.

Dynex Capital (DX)
In stark contrast, Dynex Capital is expected to see a 540% increase in EPS for Q3 2025, with analysts estimating earnings of $0.49 per share, according to GuruFocus. This significant increase in EPS is expected to drive the company's P/E ratio up to 7.17. Analysts are optimistic about the company's future prospects, with an average one-year price target of $14.13.

HBT Financial (HBT)
HBT Financial is expected to see a 1.64% increase in EPS for Q3 2025, with analysts estimating earnings of $0.57 per share, according to GuruFocus. This modest increase in EPS is expected to drive the company's P/E ratio to 9.38. The company has shown consistent growth in its financial performance, with analysts maintaining a positive outlook.

Conclusion
The upcoming earnings reports from Summit Therapeutics, Cleveland-Cliffs, Dynex Capital, and HBT Financial promise to provide valuable insights into the financial health of these companies. While Summit Therapeutics and Cleveland-Cliffs face significant challenges, Dynex Capital and HBT Financial are expected to report strong earnings growth. Investors should closely monitor these earnings reports and the subsequent market reactions to make informed investment decisions.